Related coverage linked through entity extraction aliases.
Jul 14, 2026
Nationwide FDA recalls include generic Adderall XR (mix-up), levothyroxine (subpotent), Gas-X (coolant contamination), and several prescription drugs classed as Class II. Moringa dietary supplements are under Class I recall due to serious health risks. Consumers are advised to check lot numbers and consult pharmacists.
Jul 13, 2026
Aquestive Therapeutics disclosed FDA deficiencies in its Anaphylm NDA, halting labeling discussions and causing a 37% stock drop. The setback does not represent a final rejection, leaving a path for resubmission.
May 07, 2026
Slow up-dosing peanut OIT enabled 82% of toddlers to tolerate 3.5 peanuts after treatment. Low-dose OIT was safe in preschoolers with single or multiple food allergies. Allergist guidance on anxiety was linked to reduced caregiver worry.
Mar 20, 2026
Aquestive Therapeutics received a Complete Response Letter from the FDA for Anaphylm (dibutepinephrine) sublingual film, citing deficiencies in human factors validation and packaging. The company plans to resubmit as early as Q3 2026.
Feb 16, 2026
CSL Seqirus announced that neffy adrenaline nasal spray has been approved in Australia for emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over, marking the first new adrenaline administration method approved in over 30 years.
